Security key
26253C201
DSS, INC. - Common Stock, par value $0.02 per share (DSS)
CUSIP: 26253C201
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.02 per share
- Total 13F shares
- 163,693
- Total 13F value
- $153,880
- Share change
- -884
- SEC-reported price per share
- $0.94
- Number of holders
- 16
- Value change
- -$831
- Number of buys
- 6
- Number of sells
- 3
- Shares outstanding
- 30,488,662
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
16
Top holders
10
DSS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
DSS, INC. SEC filings
DSS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26253C201
Recent filing periods:
Ownership snapshot
Top reported holders of DSS - DSS, INC. - Common Stock, par value $0.02 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Global BioMedical Pte. Ltd.
Disclosed value leader
Global BioMedical Pte. Ltd.
Comparable rows
0/15
Latest evidence
31 Mar 2025
3/4/5
13F
Highest disclosed value: $1,012,980
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Global BioMedical Pte. Ltd. has the largest disclosed position value at $1.01M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Global BioMedical Pte. Ltd.'s linked filing trail.
Disclosed position value
Top 5
Global BioMedical Pte. Ltd.
$1.01M
Frank D. Heuszel
$172K
CITADEL ADVISORS LLC
$50.6K
RENAISSANCE TECHNOLOGIES LLC
$22.8K
VANGUARD GROUP INC
$18.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Global BioMedical Pte. Ltd. |
3/4/5
Former 10% Owner
|
—
denominator unverified
|
$1,012,980
7,732,671 shares
|
— | 08 Sep 2021 |
| Frank D. Heuszel |
3/4/5
Chief Executive Officer, Director
|
—
denominator unverified
|
$171,974
1,312,776 shares
|
— | 10 Apr 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$50,581
58,333 shares
|
— | 31 Mar 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$22,762
26,248 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$18,840
21,730 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$18,189
20,977 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
163,693
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q2 2026 Across Filers
Q2 2026 holders
15
Q2 2025 holders
16
Holder diff
1
| Investor | Q2 2026 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q2 2026 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend